Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Oct 5;7(2):E408-20.
doi: 10.1208/aapsj070241.

A pragmatic approach to the design of population pharmacokinetic studies

Affiliations
Review

A pragmatic approach to the design of population pharmacokinetic studies

Amit Roy et al. AAPS J. .

Abstract

The publication of a seminal article on nonlinear mixed-effect modeling led to a revolution in pharmacokinetics (PKs) with the introduction of the population approach. Since then, interest in obtaining accurate and precise estimates of population PK parameters has led to work on population PK study design that extended previous work on optimal sampling designs for individual PK parameter estimation. The issues and developments in the design of population PK studies are reviewed as a prelude to investigating, via simulation, the performance of 2 approaches (population Fisher information matrix D-optimal design and informative block [profile] randomized [IBR] design) for designing population PK studies. The results of our simulation study indicate that the designs based on the 2 approaches yielded efficient parameter estimates. The designs based on the 2 approaches performed similarly, and in some cases designs based on the IBR approach were slightly better. The ease with which the IBR designs can be generated makes them preferable in drug development, where pragmatism and time are of great consideration. We, therefore, refer to the IBR designs as pragmatic designs. Pragmatic designs that achieve high efficiency in the estimation parameters should be used in the design of population PK studies, and simulation should be used to determine the efficiency of the designs.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of population pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5:445–479. doi: 10.1007/BF01061728. - DOI - PubMed
    1. Beal SL, Sheiner LB. Estimating population pharmacokinetics. Crit Rev Biomed Eng. 1982;8:195–222. - PubMed
    1. Guidance for Industry: Population Pharmacokinetics. Washington, DC: United States Food and Drug Administration; 1999.
    1. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters III. Monoexponential model: Clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983;11:303–319. doi: 10.1007/BF01061870. - DOI - PubMed
    1. al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm. 1990;18:347–360. doi: 10.1007/BF01062273. - DOI - PubMed

LinkOut - more resources